Aman Buzdar

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Postmenopause

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Buzdar Aman U
Medical oncology: Endocrine-therapy-related symptoms and breast cancer.
Buzdar A U
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
Peintinger F; Buzdar A U; Kuerer H M; Mejia J A; Hatzis C; Gonzalez-Angulo A M; Pusztai L; Esteva F J; Dawood S S; Green M C; Hortobagyi G N; Symmans W F
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Aman Buzdar (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Buzdar Aman U
Medical oncology: Endocrine-therapy-related symptoms and breast cancer.
Nature reviews. Clinical oncology 2009;6(6):309-10.
2009: Buzdar A U
Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(6):993-9.
2008: Peintinger F; Buzdar A U; Kuerer H M; Mejia J A; Hatzis C; Gonzalez-Angulo A M; Pusztai L; Esteva F J; Dawood S S; Green M C; Hortobagyi G N; Symmans W F
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(12):2020-5.
2008: Dawood Shaheenah; Broglio Kristine; Gonzalez-Angulo Ana M; Buzdar Aman U; Hortobagyi Gabriel N; Giordano Sharon H
Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4891-8.
2008: Buzdar Aman U
Fulvestrant--a novel estrogen receptor antagonist for the treatment of advanced breast cancer.
Drugs of today (Barcelona, Spain : 1998) 2008;44(9):679-92.
2008: Litton Jennifer K; Gonzalez-Angulo Ana M; Warneke Carla L; Buzdar Aman U; Kau Shu-Wan; Bondy Melissa; Mahabir Somdat; Hortobagyi Gabriel N; Brewster Abenaa M
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4072-7.
2008: Sestak Ivana; Cuzick Jack; Sapunar Francisco; Eastell Richard; Forbes John F; Bianco Angelo R; Buzdar Aman U;
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
The lancet oncology 2008;9(9):866-72.
2008: Jeruss Jacqueline S; Mittendorf Elizabeth A; Tucker Susan L; Gonzalez-Angulo Ana M; Buchholz Thomas A; Sahin Aysegul A; Cormier Janice N; Buzdar Aman U; Hortobagyi Gabriel N; Hunt Kelly K
Staging of breast cancer in the neoadjuvant setting.
Cancer research 2008;68(16):6477-81.
2008: Brewster Abenaa M; Hortobagyi Gabriel N; Broglio Kristine R; Kau Shu-Wan; Santa-Maria Cesar A; Arun Banu; Buzdar Aman U; Booser Daniel J; Valero Vincente; Bondy Melissa; Esteva Francisco J
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
Journal of the National Cancer Institute 2008;100(16):1179-83.
2008: Buzdar Aman U
Clinical experience with epothilones in patients with breast cancer.
Clinical breast cancer 2008;8 Suppl 2():S71-8.
2008: Gralow Julie R; Burstein Harold J; Wood William; Hortobagyi Gabriel N; Gianni Luca; von Minckwitz Gunter; Buzdar Aman U; Smith Ian E; Symmans William F; Singh Baljit; Winer Eric P
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(5):814-9.
2008: Buzdar Aman U; Coombes R Charles; Goss Paul E; Winer Eric P
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer.
Cancer 2008;112(3 Suppl):700-9.
2008: Come Steven E; Buzdar Aman U; Ingle James N; Johnston Stephen R D; Brodie Angela M; Coombes R Charles; Miller William R; Pritchard Kathleen I; Winer Eric P; Zujewski Jo Anne; Goss Paul E
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Cancer 2008;112(3 Suppl):673-8.
2008: Boughey Judy C; Buzdar Aman U; Hunt Kelly K
Recent advances in the hormonal treatment of breast cancer.
Current problems in surgery 2008;45(1):13-55.
2008: Boughey Judy C; Buzdar Aman U; Hunt Kelly K
In brief.
Current problems in surgery 2008;45(1):6-11.
2008: Jeruss Jacqueline S; Mittendorf Elizabeth A; Tucker Susan L; Gonzalez-Angulo Ana M; Buchholz Thomas A; Sahin Aysegul A; Cormier Janice N; Buzdar Aman U; Hortobagyi Gabriel N; Hunt Kelly K
Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):246-52.
2007: Buzdar Aman U
Preoperative chemotherapy treatment of breast cancer--a review.
Cancer 2007;110(11):2394-407.
2007: Deshmane Vijayalaxmi; Krishnamurthy S; Melemed Allen S; Peterson Patrick; Buzdar Aman U
Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(31):4967-73.
2007: Symmans W Fraser; Peintinger Florentia; Hatzis Christos; Rajan Radhika; Kuerer Henry; Valero Vicente; Assad Lina; Poniecka Anna; Hennessy Bryan; Green Marjorie; Buzdar Aman U; Singletary S Eva; Hortobagyi Gabriel N; Pusztai Lajos
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4414-22.
2007: Cristofanilli Massimo; Valero Vicente; Buzdar Aman U; Kau Shu-Wan; Broglio Kristine R; Gonzalez-Angulo Ana Maria; Sneige Nour; Islam Rabiul; Ueno Naoto T; Buchholz Thomas A; Singletary Sonja E; Hortobagyi Gabriel N
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
Cancer 2007;110(7):1436-44.
2007: Dawood Shaheenah; Gonzalez-Angulo Ana M; Peintinger Florentia; Broglio Kristine; Symmans William F; Kau Shu-Wan; Islam Rabiul; Hortobagyi Gabriel N; Buzdar Aman U
Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
Cancer 2007;110(6):1195-200.
2007: Gonzalez-Angulo Ana M; Hennessy Bryan T; Broglio Kristine; Meric-Bernstam Funda; Cristofanilli Massimo; Giordano Sharon H; Buchholz Thomas A; Sahin Aysegul; Singletary S Eva; Buzdar Aman U; Hortobágyi Gabriel N
Trends for inflammatory breast cancer: is survival improving?
The oncologist 2007;12(8):904-12.
2007: Buzdar Aman U
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(15):2147-8; author reply 2148.
2007: Buzdar Aman U
Adjuvant chemotherapy for high-risk operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1642-4.
2007: Mazouni C; Kau S-W; Frye D; Andre F; Kuerer H M; Buchholz T A; Symmans W F; Anderson K; Hess K R; Gonzalez-Angulo A M; Hortobagyi G N; Buzdar A U; Pusztai L
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(5):874-80.
2007: Mazouni Chafika; Hall Angeline; Broglio Kristine; Fritsche Herbert; Andre Fabrice; Esteva Francisco J; Hortobagyi Gabriel N; Buzdar Aman U; Pusztai Lajos; Cristofanilli Massimo
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Cancer 2007;109(3):496-501.
2007: Gonzalez Ricardo J; Buzdar Aman U; Fraser Symmans W; Yen Tina W; Broglio Kristine R; Lucci Anthony; Esteva Francisco J; Yin Guosheng; Kuerer Henry M
Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
The breast journal 2007;13(1):72-5.
2007: Buzdar Aman U; Valero Vicente; Ibrahim Nuhad K; Francis Deborah; Broglio Kristine R; Theriault Richard L; Pusztai Lajos; Green Marjorie C; Singletary Sonja E; Hunt Kelly K; Sahin Aysegul A; Esteva Francisco; Symmans William F; Ewer Michael S; Buchholz Thomas A; Hortobagyi Gabriel N
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(1):228-33.
2007: Esteva Francisco J; Wang Jing; Lin Feng; Mejia Jaime A; Yan Kai; Altundag Kadri; Valero Vicente; Buzdar Aman U; Hortobagyi Gabriel N; Symmans W Fraser; Pusztai Lajos
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer.
Breast cancer research : BCR 2007;9(6):R87.
2006: Peintinger Florentia; Kuerer Henry M; Anderson Keith; Boughey Judy C; Meric-Bernstam Funda; Singletary S Eva; Hunt Kelly K; Whitman Gary J; Stephens Tanya; Buzdar Aman U; Green Marjorie C; Symmans W Fraser
Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.
Annals of surgical oncology 2006;13(11):1443-9.
2006: Boughey Judy C; Peintinger Florentia; Meric-Bernstam Funda; Perry Allison C; Hunt Kelly K; Babiera Gildy V; Singletary S E; Bedrosian Isabelle; Lucci Anthony; Buzdar Aman U; Pusztai Lajos; Kuerer Henry M
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer.
Annals of surgery 2006;244(3):464-70.
2006: Buzdar Aman U; Robertson John F R
Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of breast cancer.
The Annals of pharmacotherapy 2006;40(9):1572-83.
2006: Hess Kenneth R; Anderson Keith; Symmans W Fraser; Valero Vicente; Ibrahim Nuhad; Mejia Jaime A; Booser Daniel; Theriault Richard L; Buzdar Aman U; Dempsey Peter J; Rouzier Roman; Sneige Nour; Ross Jeffrey S; Vidaurre Tatiana; Gómez Henry L; Hortobagyi Gabriel N; Pusztai Lajos
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(26):4236-44.
2006: Peintinger Florentia; Symmans W Fraser; Gonzalez-Angulo Ana M; Boughey Judy C; Buzdar Aman U; Yu T Kuan; Hunt Kelly K; Singletary S Eva; Babiera Gildy V; Lucci Anthony; Meric-Bernstam Funda; Kuerer Henry M
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
Cancer 2006;107(6):1248-54.
2006: Buzdar Aman; Chlebowski Rowan; Cuzick Jack; Duffy Sean; Forbes John; Jonat Walter; Ravdin Peter
Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.
Current medical research and opinion 2006;22(8):1575-85.
2006: Buzdar Aman U; Guastalla Jean-Paul; Nabholtz Jean-Marc; Cuzick Jack; ATAC Trialists' Group
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Cancer 2006;107(3):472-80.
2006: Buchholz Thomas A; Strom Eric A; Oswald Mary Jane; Perkins George H; Oh Julia; Domain Delora; Yu Tse-Kuan; Woodward Wendy A; Tereffe Welela; Singletary S Eva; Thomas Eva; Buzdar Aman U; Hortobagyi Gabriel N; McNeese Marsha D
Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
International journal of radiation oncology, biology, physics 2006;65(4):1155-60.
2006: Buzdar Aman U
Anastrozole for breast cancer: recent advances and ongoing challenges.
Expert review of anticancer therapy 2006;6(6):839-48.
2006: Buzdar Aman U
Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2409-11.
2006: Hanrahan Emer O; Broglio Kristine; Frye Deborah; Buzdar Aman U; Theriault Richard L; Valero Vicente; Booser Daniel J; Singletary Sonja E; Strom Eric A; Gajewski James L; Champlin Richard E; Hortobagyi Gabriel N
Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years.
Cancer 2006;106(11):2327-36.
2006: Buzdar Aman U
Update on the management of inflammatory breast cancer.
Clinical advances in hematology & oncology : H&O 2006;4(5):344-5.
2006: Cataliotti Luigi; Buzdar Aman U; Noguchi Shinzaburo; Bines Jose; Takatsuka Yuichi; Petrakova Katarina; Dube Pierre; de Oliveira Celia Tosello
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Cancer 2006;106(10):2095-103.
2006: Buzdar Aman U; Baum Michael; Cuzick Jack
Letrozole or tamoxifen in early breast cancer.
The New England journal of medicine 2006;354(14):1528-30; author reply 1528-30.
2006: Guarneri Valentina; Broglio Kristine; Kau Shu-Wan; Cristofanilli Massimo; Buzdar Aman U; Valero Vicente; Buchholz Thomas; Meric Funda; Middleton Lavinia; Hortobagyi Gabriel N; Gonzalez-Angulo Ana M
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1037-44.
2006: Hennessy Bryan T; Gonzalez-Angulo Ana Maria; Hortobagyi Gabriel N; Cristofanilli Massimo; Kau Shu Wan; Broglio Kristine; Fornage Bruno; Singletary S Eva; Sahin Aysegul; Buzdar Aman U; Valero Vicente
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Cancer 2006;106(5):1000-6.
2006: Buzdar Aman U
Dietary modification and risk of breast cancer.
JAMA : the journal of the American Medical Association 2006;295(6):691-2.
2006: Buzdar Aman U; Cuzick Jack
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):1037s-1048s.
2006: Come Steven E; Buzdar Aman U; Ingle James N; Arteaga Carlos L; Brown Myles; Dowsett Mitch; Hilsenbeck Susan G; Kumar Rakesh; Johnston Stephen R D; Lee Adrian V; Paik Soonmyung; Pritchard Kathleen I; Winer Eric P; Hart Carol
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 2):997s-1000s.
2006: Chagpar Anees B; Middleton Lavinia P; Sahin Aysegul A; Dempsey Peter; Buzdar Aman U; Mirza Attiqa N; Ames Fredrick C; Babiera Gildy V; Feig Barry W; Hunt Kelly K; Kuerer Henry M; Meric-Bernstam Funda; Ross Merrick I; Singletary S Eva
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Annals of surgery 2006;243(2):257-64.
2006: Yamaya Hidetoshi; Saeki Mayuko; Yoshida Ken-ichiro; Shibata Jiro; Yano Shingo; Sato Yoshiaki; Takao Atsushi; Shindo Takashi; Buzdar Aman U; Nagayama Sekio
Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C]TAS-108) and its metabolites after single oral administration to rats bearing 7,12-dimethylbenz(alpha)anthracene-induced mammary tumor.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(2):331-8.
2005: Hennessy Bryan T; Hortobagyi Gabriel N; Rouzier Roman; Kuerer Henry; Sneige Nour; Buzdar Aman U; Kau Shu Wan; Fornage Bruno; Sahin Aysegul; Broglio Kristine; Singletary S Eva; Valero Vicente
Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9304-11.
2005: Giordano Sharon H; Perkins George H; Broglio Kristine; Garcia Sherry G; Middleton Lavinia P; Buzdar Aman U; Hortobagyi Gabriel N
Adjuvant systemic therapy for male breast carcinoma.
Cancer 2005;104(11):2359-64.
2005: Buzdar Aman U; Cuzick Jack
Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8544-6; author reply 8546-7.
2005: Rouzier Roman; Pusztai Lajos; Delaloge Suzette; Gonzalez-Angulo Ana M; Andre Fabrice; Hess Kenneth R; Buzdar Aman U; Garbay Jean-Remi; Spielmann Marc; Mathieu Marie-Christine; Symmans W Fraser; Wagner Peter; Atallah David; Valero Vicente; Berry Donald A; Hortobagyi Gabriel N
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(33):8331-9.
2005: Gonzalez-Angulo Ana M; McGuire Sean E; Buchholz Thomas A; Tucker Susan L; Kuerer Henry M; Rouzier Roman; Kau Shu-Wan; Huang Eugene H; Morandi Paolo; Ocana Alberto; Cristofanilli Massimo; Valero Vicente; Buzdar Aman U; Hortobagyi Gabriel N
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7098-104.
2005: Yamaya H; Yoshida K; Kuritani J; Yonezawa J; Tsuda M; Shindo T; Nagayama S; Buzdar A U
Safety, tolerability, and pharmacokinetics of TAS-108 in normal healthy post-menopausal female subjects: a phase I study on single oral dose.
Journal of clinical pharmacy and therapeutics 2005;30(5):459-70.
2005: Green Marjorie C; Buzdar Aman U; Smith Terry; Ibrahim Nuhad K; Valero Vicente; Rosales Marguerite F; Cristofanilli Massimo; Booser Daniel J; Pusztai Lajos; Rivera Edgardo; Theriault Richard L; Carter Cynthia; Frye Debra; Hunt Kelly K; Symmans W Fraser; Strom Eric A; Sahin Aysegul A; Sikov William; Hortobagyi Gabriel N
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5983-92.
2005: Hanrahan Emer O; Broglio Kristine R; Buzdar Aman U; Theriault Richard L; Valero Vicente; Cristofanilli Massimo; Yin Guosheng; Kau Shu-Wan C; Hortobagyi Gabriel N; Rivera Edgardo
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors.
Cancer 2005;104(6):1158-71.
2005: Montero Alberto J; Rouzier Roman; Lluch Ana; Theriault Richard L; Buzdar Aman U; Delaloge Suzette; Bermejo Begoñia; Le Monique; Kau Shu-Wan; Dunant Ariane; Arriagada Rodrigo; Spielmann Marc; Garcia-Conde Javier; Sahin Aysegul A; Singletary Sonja E; Hortobagyi Gabriel N; Valero Vicente
The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
Cancer 2005;104(2):229-35.
2005: Huang Eugene H; Tucker Susan L; Strom Eric A; McNeese Marsha D; Kuerer Henry M; Hortobagyi Gabriel N; Buzdar Aman U; Valero Vicente; Perkins George H; Schechter Naomi R; Hunt Kelly K; Sahin Aysegul A; Buchholz Thomas A
Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
International journal of radiation oncology, biology, physics 2005;62(2):351-7.
2005: Gonzalez-Angulo Ana M; Broglio Kristine; Kau Shu-Wan; Eralp Yesmin; Erlichman Julie; Valero Vicente; Theriault Richard; Booser Daniel; Buzdar Aman U; Hortobagyi Gabriel N; Arun Banu
Women age < or = 35 years with primary breast carcinoma: disease features at presentation.
Cancer 2005;103(12):2466-72.
2005: Buzdar Aman U; Ibrahim Nuhad K; Francis Deborah; Booser Daniel J; Thomas Eva S; Theriault Richard L; Pusztai Lajos; Green Marjorie C; Arun Banu K; Giordano Sharon H; Cristofanilli Massimo; Frye Debra K; Smith Terry L; Hunt Kelly K; Singletary Sonja E; Sahin Aysegul A; Ewer Michael S; Buchholz Thomas A; Berry Donald; Hortobagyi Gabriel N
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3676-85.
2005: Howell Anthony; Buzdar Aman
Are aromatase inhibitors superior to antiestrogens?
The Journal of steroid biochemistry and molecular biology 2005;93(2-5):237-47.
2005: Buzdar Aman U
TAS-108: a novel steroidal antiestrogen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):906s-8s.
2005: Come Steven E; Buzdar Aman U; Ingle James N; Arteaga Carlos L; Brodie Angela M; Colditz Graham A; Johnston Stephen R D; Kristensen Vessela N; Lønning Per E; McDonnell Donald P; Osborne C Kent; Russo Jose; Santen Richard J; Yee Douglas; Hart Carol S
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 2):861s-4s.
2005: Yamamoto Yasuji; Shibata Jiro; Yonekura Kazuhiko; Sato Kouji; Hashimoto Akihiro; Aoyagi Yoshimi; Wierzba Konstanty; Yano Shingo; Asao Tetsuji; Buzdar Aman U; Terada Tadafumi
TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):315-22.
2005: Buzdar Aman; Macahilig Cynthia
How rapidly do oncologists respond to clinical trial data?
The oncologist 2005;10(1):15-21.
2005: Cristofanilli Massimo; Gonzalez-Angulo Ana; Sneige Nour; Kau Shu-Wan; Broglio Kristine; Theriault Richard L; Valero Vicente; Buzdar Aman U; Kuerer Henry; Buccholz Thomas A; Hortobagyi Gabriel N
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(1):41-8.
2005: Buzdar Aman U
Aromatase inhibitors: changing the face of endocrine therapy for breast cancer.
Breast disease 2005;24():107-17.
2004: Huang Eugene H; Tucker Susan L; Strom Eric A; McNeese Marsha D; Kuerer Henry M; Buzdar Aman U; Valero Vicente; Perkins George H; Schechter Naomi R; Hunt Kelly K; Sahin Aysegul A; Hortobagyi Gabriel N; Buchholz Thomas A
Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(23):4691-9.
2004: Yu Tse-Kuan; Whitman Gary J; Thames Howard D; Buzdar Aman U; Strom Eric A; Perkins George H; Schechter Naomi R; McNeese Marsha D; Kau Shu-Wan; Thomas Eva S; Hortobagyi Gabriel N; Buchholz Thomas A
Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients.
Journal of the National Cancer Institute 2004;96(22):1676-81.
2004: Gonzalez-Angulo Ana M; Cristofanilli Massimo; Strom Eric A; Buzdar Aman U; Kau Shu-Wan; Broglio Kristine R; Smith Terry L; Hortobagyi Gabriel N
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment.
Cancer 2004;101(8):1760-6.
2004: Li Zhiyong; Ibrahim Nuhad K; Wathen Jay K; Wang Michael; Mante Menchu Rosario P; Valero Vicente; Theriault Richard; Buzdar Aman U; Hortobagyi Gabriel N
Colitis in patients with breast carcinoma treated with taxane-based chemotherapy.
Cancer 2004;101(7):1508-13.
2004: Morandi Paolo; Rouzier Roman; Altundag Kadri; Buzdar Aman U; Theriault Richard L; Hortobagyi Gabriel
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Cancer 2004;101(7):1482-9.
2004: Buzdar Aman U
Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.
Drugs of today (Barcelona, Spain : 1998) 2004;40(9):751-64.
2004: Gonzalez-Angulo Ana M; Sneige Nour; Buzdar Aman U; Valero Vicente; Kau Shu-Wan; Broglio Kristine; Yamamura Yuko; Hortobagyi Gabriel N; Cristofanilli Massimo
p53 expression as a prognostic marker in inflammatory breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(18 Pt 1):6215-21.
2004: Jones Kellie L; Buzdar Aman U
A review of adjuvant hormonal therapy in breast cancer.
Endocrine-related cancer 2004;11(3):391-406.
2004: Buzdar Aman U
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Clinical breast cancer 2004;5 Suppl 1():S6-S12.
2004: Buzdar Aman U
Current developments in hormonal therapy of breast cancer.
Clinical breast cancer 2004;5 Suppl 1():S4-5.
2004: Resetkova Erika; Gonzalez-Angulo Ana M; Sneige Nour; Mcdonnell Timothy J; Buzdar Aman U; Kau Shu Wan; Yamamura Yuko; Reuben James M; Hortobagyi Gabriel N; Cristofanilli Massimo
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma.
Cancer 2004;101(5):913-7.
2004: Blakely L Johnetta; Buzdar Aman; Chang Hsiu-Yin; Frye Debra; Theriault Richard; Valero Vicente; Rivera Edgardo; Booser Daniel; Kuritani Jun; Tsuda Masuhiro
A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5425-31.
2004: Buzdar Aman U
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3199-200; author reply 3200-1.
2004: Buchholz Thomas A; Huang Eugene H; Berry Donald; Pusztai Lajos; Strom Eric A; McNeese Marsha D; Perkins George H; Schechter Naomi R; Kuerer Henry M; Buzdar Aman U; Valero Vicente; Hunt Kelly K; Hortobagyi Gabriel N; Sahin Aysegul A
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
International journal of radiation oncology, biology, physics 2004;59(5):1337-42.
2004: Wefel Jeffrey S; Lenzi Renato; Theriault Richard; Buzdar Aman U; Cruickshank Scott; Meyers Christina A
'Chemobrain' in breast carcinoma?: a prologue.
Cancer 2004;101(3):466-75.
2004: Gonzalez-Angulo Ana M; Krishnamurthy Savitri; Yamamura Yuko; Broglio Kristine R; Pusztai Lajos; Buzdar Aman U; Hortobagyi Gabriel N; Esteva Francisco J
Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma.
Cancer 2004;101(2):258-63.
2004: Giordano Sharon H; Cohen Deborah S; Buzdar Aman U; Perkins George; Hortobagyi Gabriel N
Breast carcinoma in men: a population-based study.
Cancer 2004;101(1):51-7.
2004: Thomas Eva; Holmes Frankie A; Smith Terry L; Buzdar Aman U; Frye Debra K; Fraschini Giuseppe; Singletary S Eva; Theriault Richard L; McNeese Marsha D; Ames Frederick; Walters Ronald; Hortobagyi Gabriel N
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2294-302.
2004: Buzdar Aman U; Vergote Ignace; Sainsbury Richard
The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: a review of data from first-line metastatic disease trials in postmenopausal women.
The breast journal 2004;10(3):211-7.
2004: Garg Amit K; Strom Eric A; McNeese Marsha D; Buzdar Aman U; Hortobagyi Gabriel N; Kuerer Henry M; Perkins George H; Singletary S Eva; Hunt Kelly K; Sahin Asyegul; Schechter Naomi; Valero Vicente; Tucker Susan L; Buchholz Thomas A
T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy.
International journal of radiation oncology, biology, physics 2004;59(1):138-45.
2004: Buzdar Aman U
Preoperative chemotherapy for breast cancer.
Clinical advances in hematology & oncology : H&O 2004;2(4):212, 215.
2004: Cuzick Jack; Buzdar Aman; Baum Michael; Bianco Raffaele; Coleman Robert; Constenla Manuel; Distler Wolfgang; Dowsett Mitch; Forbes John; Guastalla Jean Paul; Houghton Joan; Williams Norman; Howell Anthony; Locker Gershon; MacKey John; Sainsbury Richard; Tobias Jeffrey
Adjuvant use of anastrozole in breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1524-6; author reply 1526-7.
2004: Rajan Radhika; Poniecka Anna; Smith Terry L; Yang Ying; Frye Deborah; Pusztai Lajos; Fiterman Derek J; Gal-Gombos Eva; Whitman Gary; Rouzier Roman; Green Marjorie; Kuerer Henry; Buzdar Aman U; Hortobagyi Gabriel N; Symmans W Fraser
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Cancer 2004;100(7):1365-73.
2004: Cristofanilli Massimo; Gonzalez-Angulo Ana Maria; Buzdar Aman U; Kau Shu-Wan; Frye Debbie K; Hortobagyi Gabriel N
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience.
Clinical breast cancer 2004;4(6):415-9.
2004: Buzdar Aman U
Letrozole in breast cancer.
The New England journal of medicine 2004;350(7):727-30; author reply 727-30.
2004: Esteva Francisco J; Sahin Aysegul A; Smith Terry L; Yang Ying; Pusztai Lajos; Nahta Rita; Buchholz Thomas A; Buzdar Aman U; Hortobagyi Gabriel N; Bacus Sarah S
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Cancer 2004;100(3):499-506.
2004: Blakely L Johnetta; Buzdar Aman U; Lozada Jose A; Shullaih Samer A; Hoy Emma; Smith Terry L; Hortobagyi Gabriel N
Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence.
Cancer 2004;100(3):465-9.
2004: Buzdar Aman U
Hormonal therapy in early and advanced breast cancer.
The breast journal 2004;10 Suppl 1():S19-21.
2004: Buzdar Aman U
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 2):355S-61S.
2004: Come Steven E; Buzdar Aman U; Arteaga Carlos L; Bissell Mina J; Brown Myles A; Ellis Matthew J; Goss Paul E; Green Jeffrey E; Ingle James N; Lee Adrian V; Medina Daniel; Nicholson Robert I; Santen Richard J; Schiff Rachel; Hart Carol S
Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 2):327S-330S.
2004: Giordano Sharon H; Buzdar Aman U; Smith Terry L; Kau Shu-Wan; Yang Ying; Hortobagyi Gabriel N
Is breast cancer survival improving?
Cancer 2004;100(1):44-52.
2004: Buzdar Aman U
Paclitaxel in early breast cancer: a viewpoint by Aman U. Buzdar.
Drugs 2004;64(16):1848-9.
2003: Simons W Robert; Jones David; Buzdar Aman
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Clinical therapeutics 2003;25(11):2972-87.
2003: Buzdar Aman U
Aromatase inhibitors in breast cancer therapy.
Clinical breast cancer 2003;4 Suppl 2():S84-8.
2003: Baum Michael; Buzdar Aman; Howell Anthony
ATAC trial did not report interim results.
BMJ (Clinical research ed.) 2003;327(7422):1050.
2003: Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Cancer 2003;98(9):1802-10.
2003: Buzdar Aman U
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Seminars in oncology 2003;30(5 Suppl 16):21-9.
2003: Buzdar Aman U
Breast cancer in men.
Oncology (Williston Park, N.Y.) 2003;17(10):1361-4; discussion 1364, 1369-72.
2003: Buzdar Aman U; Hortobagyi Gabriel N
Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer.
Cancer treatment reviews 2003;29(5):449-52.
2003: Woodward Wendy A; Strom Eric A; Tucker Susan L; Katz Angela; McNeese Marsha D; Perkins George H; Buzdar Aman U; Hortobagyi Gabriel N; Hunt Kelly K; Sahin Aysegul; Meric Funda; Sneige Nour; Buchholz Thomas A
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation.
International journal of radiation oncology, biology, physics 2003;57(2):336-44.
2003: Woodward Wendy A; Strom Eric A; McNeese Marsha D; Perkins George H; Outlaw Eleysia L; Hortobagyi Gabriel N; Buzdar Aman U; Buchholz Thomas A
Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy.
International journal of radiation oncology, biology, physics 2003;57(2):327-35.
2003: Buzdar Aman U;
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
The Journal of steroid biochemistry and molecular biology 2003;86(3-5):399-403.
2003: Baum Michael; Buzdar Aman
The current status of aromatase inhibitors in the management of breast cancer.
The Surgical clinics of North America 2003;83(4):973-94.
2003: Robertson John F R; Osborne C Kent; Howell Anthony; Jones Stephen E; Mauriac Louis; Ellis Matthew; Kleeberg Ulrich R; Come Steven E; Vergote Ignace; Gertler Stan; Buzdar Aman; Webster Alan; Morris Charles
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Cancer 2003;98(2):229-38.
2003: Symmans W Fraser; Ayers Mark; Clark Edwin A; Stec James; Hess Kenneth R; Sneige Nour; Buchholz Thomas A; Krishnamurthy Savitri; Ibrahim Nuhad K; Buzdar Aman U; Theriault Richard L; Rosales Marguerite F M; Thomas Eva S; Gwyn Karin M; Green Marjorie C; Syed Abdul R; Hortobagyi Gabriel N; Pusztai Lajos
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
Cancer 2003;97(12):2960-71.
2003: Assikis Vasily; Buzdar Aman; Yang Ying; Smith Terry; Theriault Richard; Booser Daniel; Valero Vicente; Walters Ronald; Singletary Eva; Ames Frederick; Hortobagyi Gabriel
A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up.
Cancer 2003;97(11):2716-23.
2003: Montemurro Filippo; Rondón Gabriela; Munsell Mark; Smith Terry L; Donato Michele L; Gajewski James L; Rahman Zia U; Buzdar Aman U; Champlin Richard E; Ueno Naoto T
Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2003;9(5):330-40.
2003: Allred D Craig; Baum Michael; Buzdar Aman U; Carlson Robert W; Dowsett Mitchell; Elledge Richard M; Gradishar William J; Grana Generosa; Howell Anthony; Mamounas Eleftherios P
A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
The breast journal 2003;9(3):213-22.
2003: Buzdar Aman
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Clinical breast cancer 2003;4 Suppl 1():S42-8.
2003: Zhang Fan; Yang Ying; Smith Terry; Kau Shu-Wan; McConathy Judy M; Esteva Francisco J; Kuerer Henry M; Symmans W Fraser; Buzdar Aman U; Hortobagyi Gabriel N; Pusztai Lajos
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
Cancer 2003;97(7):1758-65.
2003: Buzdar Aman; O'Shaughnessy Joyce A; Booser Daniel J; Pippen John E; Jones Stephen E; Munster Pamela N; Peterson Patrick; Melemed Allen S; Winer Eric; Hudis Clifford
Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1007-14.
2003: Hess Kenneth R; Pusztai Lajos; Buzdar Aman U; Hortobagyi Gabriel N
Estrogen receptors and distinct patterns of breast cancer relapse.
Breast cancer research and treatment 2003;78(1):105-18.
2003: Buzdar Aman U
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):468S-72S.
2003: Come Steven E; Buzdar Aman U; Arteaga Carlos L; Brodie Angela M; Davidson Nancy E; Dowsett Mitch; Ingle James N; Johnston Stephen R D; Lee Adrian V; Osborne C Kent; Pritchard Kathleen I; Vogel Victor G; Winer Eric P; Hart Carol S
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1 Pt 2):443S-6S.
2003: Buzdar Aman U
Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
The oncologist 2003;8(4):335-41.
2003: Cristofanilli Massimo; Buzdar Aman U; Hortobágyi Gabriel N
Update on the management of inflammatory breast cancer.
The oncologist 2003;8(2):141-8.
2002: Buzdar Aman U
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Expert review of anticancer therapy 2002;2(6):623-9.
2002: Giordano Sharon H; Booser Daniel J; Murray James L; Ibrahim Nuhad K; Rahman Zia U; Valero Vicente; Theriault Richard L; Rosales Marguerite F; Rivera Edgardo; Frye Debbie; Ewer Michael; Ordonez Nelson G; Buzdar Aman U; Hortobagyi Gabriel N
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(11):3360-8.
2002: Buzdar Aman U; Robertson John F R; Eiermann Wolfgang; Nabholtz Jean-Marc
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Cancer 2002;95(9):2006-16.
2002: Valero Vicente; Buzdar Aman U; McNeese Marsha; Singletary Eva; Hortobagyi Gabriel N
Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience.
Clinical breast cancer 2002;3 Suppl 2():S63-8.
2002: Giordano Sharon H; Buzdar Aman U; Hortobagyi Gabriel N
Breast cancer in men.
Annals of internal medicine 2002;137(8):678-87.
2002: Buzdar Aman U
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Breast cancer research and treatment 2002;75 Suppl 1():S13-7; discussion S33-5.
2002: Osborne C K; Pippen J; Jones S E; Parker L M; Ellis M; Come S; Gertler S Z; May J T; Burton G; Dimery I; Webster A; Morris C; Elledge R; Buzdar A
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3386-95.
2002: Huang Eugene; McNeese Marsha D; Strom Eric A; Perkins George H; Katz Angela; Hortobagyi Gabriel N; Valero Vicente; Kuerer Henry M; Singletary S Eva; Hunt Kelly K; Buzdar Aman U; Buchholz Thomas A
Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer.
International journal of radiation oncology, biology, physics 2002;53(5):1225-33.
2002: Buchholz Thomas A; Katz Angela; Strom Eric A; McNeese Marsha D; Perkins George H; Hortobagyi Gabriel N; Thames Howard D; Kuerer Henry M; Singletary S Eva; Sahin Aysegul A; Hunt Kelly K; Buzdar Aman U; Valero Vicente; Sneige Nour; Tucker Susan L
Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy.
International journal of radiation oncology, biology, physics 2002;53(4):880-8.
2002: Assikis Vasily J; Buzdar Aman
Recent advances in aromatase inhibitor therapy for breast cancer.
Seminars in oncology 2002;29(3 Suppl 11):120-8.
2002: Giordano Sharon H; Valero Vicente; Buzdar Aman U; Hortobagyi Gabriel N
Efficacy of anastrozole in male breast cancer.
American journal of clinical oncology 2002;25(3):235-7.
2002: Buzdar A; Hayes D; El-Khoudary A; Yan S; Lønning P; Lichinitser M; Gopal R; Falkson G; Pritchard K; Lipton A; Wolter K; Lee A; Fly K; Chew R; Alderdice M; Burke K; Eisenber P;
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Breast cancer research and treatment 2002;73(2):161-75.
2002: Buzdar Aman U; Singletary S Eva; Valero Vicente; Booser Daniel J; Ibrahim Nuhad K; Rahman Zia; Theriault Richard L; Walters Ronald; Rivera Edgardo; Smith Terry L; Holmes Frankie A; Hoy Emma; Frye Debra K; Manuel Nikki; Kau Shu-Wan; McNeese Marsha D; Strom Eric; Thomas Eva; Hunt Kelly; Ames Fred; Berry Donald; Hortobagyi Gabriel N
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):1073-9.
2002: Newman Lisa A; Buzdar Aman U; Singletary S Eva; Kuerer Henry M; Buchholz Thomas; Ames Frederick C; Ross Merrick I; Hunt Kelly K
A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility.
Annals of surgical oncology 2002;9(3):228-34.
2002: Buzdar Aman U
Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):876-8.
2002: Rivera Edgardo; Holmes Frankie A; Buzdar Aman U; Asmar Lina; Kau Shu-Wan; Fraschini Giuseppe; Walters Ronald; Theriault Richard L; Hortobagyi Gabriel N
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.
The breast journal 2002;8(1):2-9.
2002: Buchholz Thomas A; Tucker Susan L; Masullo Lawrence; Kuerer Henry M; Erwin Jessica; Salas Jessica; Frye Debbie; Strom Eric A; McNeese Marsha D; Perkins George; Katz Angela; Singletary S Eva; Hunt Kelly K; Buzdar Aman U; Hortobagyi Gabriel N
Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):17-23.
2001: Johnson P E; Buzdar A
Are differences in the available aromatase inhibitors and inactivators significant?
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4360s-4368s; discussion 4411s-4412s.
2001: Buzdar A U; Come S E; Brodie A; Ellis M; Goss P E; Ingle J N; Johnston S R; Lee A V; Osborne C K; Vogel V G; Hart C S
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12 Suppl):4335s-4337s; discussion 4411s-4412s.
2001: Buzdar A U
A summary of second-line randomized studies of aromatase inhibitors.
The Journal of steroid biochemistry and molecular biology 2001;79(1-5):109-14.
2001: Kuerer H M; Singletary S E; Buzdar A U; Ames F C; Valero V; Buchholz T A; Ross M I; Pusztai L; Hortobagyi G N; Hunt K K
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma.
American journal of surgery 2001;182(6):601-8.
2001: Bonneterre J; Buzdar A; Nabholtz J M; Robertson J F; Thürlimann B; von Euler M; Sahmoud T; Webster A; Steinberg M;
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Cancer 2001;92(9):2247-58.
2001: Xiong Q; Valero V; Kau V; Kau S W; Taylor S; Smith T L; Buzdar A U; Hortobagyi G N; Theriault R L
Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience.
Cancer 2001;92(10):2523-8.
2001: Cristofanilli M; Buzdar A U; Sneige N; Smith T; Wasaff B; Ibrahim N; Booser D; Rivera E; Murray J L; Valero V; Ueno N; Singletary E S; Hunt K; Strom E; McNeese M; Stelling C; Hortobagyi G N
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
Cancer 2001;92(7):1775-82.
2001: Buzdar A; Howell A
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(9):2620-35.
2001: Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(14):3357-66.
2001: Vlastos G; Jean M E; Mirza A N; Mirza N Q; Kuerer H M; Ames F C; Hunt K K; Ross M I; Buchholz T A; Buzdar A U; Singletary S E
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases.
Annals of surgical oncology 2001;8(5):425-31.
2001: Buzdar A U
Endocrine therapy in the treatment of metastatic breast cancer.
Seminars in oncology 2001;28(3):291-304.
2001: Kuerer H M; Buzdar A U; Singletary S E
Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast.
Journal of surgical oncology 2001;77(2):139-47.
2001: Newman L A; Kuerer H M; Fornage B; Mirza N; Hunt K K; Ross M I; Ames F C; Buzdar A U; Singletary S E
Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer.
American journal of surgery 2001;181(4):313-8.
2001: Buchholz T A; Tucker S L; Erwin J; Mathur D; Strom E A; McNeese M D; Hortobagyi G N; Cristofanilli M; Esteva F J; Newman L; Singletary S E; Buzdar A U; Hunt K K
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2240-6.
2001: Münster P N; Buzdar A; Dhingra K; Enas N; Ni L; Major M; Melemed A; Seidman A; Booser D; Theriault R; Norton L; Hudis C
Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):2002-9.
2001: Ibrahim N K; Buzdar A U; Valero V; Dhingra K; Willey J; Hortobagyi G N
Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma.
Cancer 2001;91(4):664-71.
2001: Brito R A; Valero V; Buzdar A U; Booser D J; Ames F; Strom E; Ross M; Theriault R L; Frye D; Kau S W; Asmar L; McNeese M; Singletary S E; Hortobagyi G N
Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):628-33.
2001: Michaud L B; Jones K L; Buzdar A U
Combination endocrine therapy in the management of breast cancer.
The oncologist 2001;6(6):538-46.
2001: Ibrahim N K; Valero V; Rahman Z; Theriault R L; Walters R S; Buzdar A U; Booser D J; Holmes F A; Murray J L; Willey J; Bast R; Hortobagyi G N
Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation.
Cancer investigation 2001;19(5):459-66.
2001: Esteva F J; Valero V; Pusztai L; Boehnke-Michaud L; Buzdar A U; Hortobagyi G N
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.
The oncologist 2001;6(2):133-46.
2000: Ibrahim N K; Buzdar A U; Asmar L; Theriault R L; Hortobagyi G N
Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: the M.D. Anderson experience, with long-term follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(12):1597-601.
2000: Rivera E; Holmes F A; Frye D; Valero V; Theriault R L; Booser D; Walters R; Buzdar A U; Dhingra K; Fraschini G; Hortobagyi G N
Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.
Cancer 2000;89(11):2195-201.
2000: Chang S; Alderfer J R; Asmar L; Buzdar A U
Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis.
Breast cancer research and treatment 2000;64(2):157-63.
2000: Nabholtz J M; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(22):3758-67.
2000: Breslin T M; Cohen L; Sahin A; Fleming J B; Kuerer H M; Newman L A; Delpassand E S; House R; Ames F C; Feig B W; Ross M I; Singletary S E; Buzdar A U; Hortobagyi G N; Hunt K K
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3480-6.
2000: Buzdar A
Exemestane in advanced breast cancer.
Anti-cancer drugs 2000;11(8):609-16.
2000: Buzdar A U
Tamoxifen's clinical applications: old and new.
Archives of family medicine 2000;9(9):906-12.
2000: Vlastos G; Rubio I T; Mirza N Q; Newman L A; Aurora R; Alderfer J; Buzdar A U; Singletary S E
Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer.
Annals of surgical oncology 2000;7(8):581-7.
2000: Katz A; Strom E A; Buchholz T A; Thames H D; Smith C D; Jhingran A; Hortobagyi G; Buzdar A U; Theriault R; Singletary S E; McNeese M D
Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(15):2817-27.
2000: Meric F; Mirza N Q; Buzdar A U; Hunt K K; Ames F C; Ross M I; Pollock R E; Newman L A; Feig B W; Strom E A; Buchholz T A; McNeese M D; Hortobagyi G N; Singletary S E
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer.
Annals of surgical oncology 2000;7(6):435-40.
2000: Liao Z; Strom E A; Buzdar A U; Singletary S E; Hunt K; Allen P K; McNeese M D
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
International journal of radiation oncology, biology, physics 2000;47(5):1191-200.
2000: Vlastos G; Fornage B D; Mirza N Q; Bedi D; Lenert J T; Winchester D J; Tolley S M; Ames F C; Ross M I; Feig B W; Hunt K K; Buzdar A U; Singletary S E
The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy.
American journal of surgery 2000;179(6):446-52.
2000: Hoff P M; Valero V; Buzdar A U; Singletary S E; Theriault R L; Booser D; Asmar L; Frye D; McNeese M D; Hortobagyi G N
Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy.
Cancer 2000;88(9):2054-60.
2000: Michaud L B; Buzdar A U
Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
Drugs & aging 2000;16(4):261-71.
2000: Ibrahim N K; Valero V; Theriault R L; Willey J; Walters R S; Buzdar A U; Booser D J; Hortobagyi G N
Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer.
American journal of clinical oncology 2000;23(2):117-21.
2000: Vlastos G; Mirza N Q; Lenert J T; Hunt K K; Ames F C; Feig B W; Ross M I; Buzdar A U; Singletary S E
The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Cancer 2000;88(6):1417-24.
2000: Kushwaha A C; Whitman G J; Stelling C B; Cristofanilli M; Buzdar A U
Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings.
AJR. American journal of roentgenology 2000;174(2):535-8.
2000: Hortobagyi G N; Buzdar A U; Theriault R L; Valero V; Frye D; Booser D J; Holmes F A; Giralt S; Khouri I; Andersson B; Gajewski J L; Rondon G; Smith T L; Singletary S E; Ames F C; Sneige N; Strom E A; McNeese M D; Deisseroth A B; Champlin R E
Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
Journal of the National Cancer Institute 2000;92(3):225-33.
2000: Ibrahim N K; Sahin A A; Dubrow R A; Lynch P M; Boehnke-Michaud L; Valero V; Buzdar A U; Hortobagyi G N
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Lancet 2000;355(9200):281-3.
1999: Lenert J T; Vlastos G; Mirza N Q; Winchester D J; Binkley S M; Ames F C; Ross M I; Feig B W; Hunt K K; Strom E; Buzdar A U; Hortobagyi G N; Singletary S E
Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients.
Annals of surgical oncology 1999;6(8):762-7.
1999: Robertson J F; Howell A; Buzdar A; von Euler M; Lee D
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Breast cancer research and treatment 1999;58(2):157-62.
1999: Buzdar A U; Singletary S E; Theriault R L; Booser D J; Valero V; Ibrahim N; Smith T L; Asmar L; Frye D; Manuel N; Kau S W; McNeese M; Strom E; Hunt K; Ames F; Hortobagyi G N
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3412-7.
1999: Michaud L B; Buzdar A U
Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.
Drug safety : an international journal of medical toxicology and drug experience 1999;21(4):297-309.
1999: Ibrahim N K; Rahman Z; Valero V; Willey J; Theriault R L; Buzdar A U; Murray J L; Bast R; Hortobagyi G N
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.
Cancer 1999;86(7):1251-7.
1999: Buzdar A U; Hortobagyi G N
Recent advances in adjuvant therapy of breast cancer.
Seminars in oncology 1999;26(4 Suppl 12):21-7.
1999: Hortobagyi G N; Hung M C; Buzdar A U
Recent developments in breast cancer therapy.
Seminars in oncology 1999;26(4 Suppl 12):11-20.
1999: Kuerer H M; Sahin A A; Hunt K K; Newman L A; Breslin T M; Ames F C; Ross M I; Buzdar A U; Hortobagyi G N; Singletary S E
Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
Annals of surgery 1999;230(1):72-8.
1999: Buzdar A U
Role of aromatase inhibitors in advanced breast cancer.
Endocrine-related cancer 1999;6(2):219-25.
1999: Buchholz T A; Hunt K K; Amosson C M; Tucker S L; Strom E A; McNeese M D; Buzdar A U; Singletary S E; Hortobagyi G N
Sequencing of chemotherapy and radiation in lymph node-negative breast cancer.
The cancer journal from Scientific American 1999;5(3):159-64.
1999: Valero V; Buzdar A U; Theriault R L; Azarnia N; Fonseca G A; Willey J; Ewer M; Walters R S; Mackay B; Podoloff D; Booser D; Lee L W; Hortobagyi G N
Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(5):1425-34.
1999: Cristofanilli M; Holmes F A; Esparza L; Valero V; Buzdar A U; Neidhart J A; Hortobagyi G N
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Breast cancer research and treatment 1999;54(3):225-33.
1999: Holmes F A; Valero V; Walters R S; Theriault R L; Booser D J; Gibbs H; Fraschini G; Buzdar A U; Willey J; Frye D; Asmar L; Hortobagyi G N
Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):403-11.
1999: Berry D L; Theriault R L; Holmes F A; Parisi V M; Booser D J; Singletary S E; Buzdar A U; Hortobagyi G N
Management of breast cancer during pregnancy using a standardized protocol.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):855-61.
1999: Kuerer H M; Newman L A; Smith T L; Ames F C; Hunt K K; Dhingra K; Theriault R L; Singh G; Binkley S M; Sneige N; Buchholz T A; Ross M I; McNeese M D; Buzdar A U; Hortobagyi G N; Singletary S E
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(2):460-9.
1999: Rahman Z U; Frye D K; Smith T L; Asmar L; Theriault R L; Buzdar A U; Hortobagyi G N
Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference.
Cancer 1999;85(1):104-11.
1999: Ibrahim N K; Hortobagyi G N; Ewer M; Ali M K; Asmar L; Theriault R L; Fraschini G; Frye D K; Buzdar A U
Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience.
Cancer chemotherapy and pharmacology 1999;43(6):471-8.
1998: Kuerer H M; Newman L A; Buzdar A U; Hunt K K; Dhingra K; Buchholz T A; Binkley S M; Ames F C; Feig B W; Ross M I; Hortobagyi G N; Singletary S E
Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer.
American journal of surgery 1998;176(6):502-9.
1998: Kuerer H M; Newman L A; Fornage B D; Dhingra K; Hunt K K; Buzdar A U; Ames F C; Ross M I; Feig B W; Hortobagyi G N; Singletary S E
Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
Annals of surgical oncology 1998;5(8):673-80.
1998: Chang S; Buzdar A U; Hursting S D
Inflammatory breast cancer and body mass index.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3731-5.
1998: Buzdar A
The place of chemotherapy in the treatment of early breast cancer.
British journal of cancer 1998;78 Suppl 4():16-20.
1998: Buzdar A U; Jonat W; Howell A; Jones S E; Blomqvist C P; Vogel C L; Eiermann W; Wolter J M; Steinberg M; Webster A; Lee D
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Cancer 1998;83(6):1142-52.
1998: Rahman Z U; Hortobagyi G N; Buzdar A U; Champlin R
High-dose chemotherapy with autologous stem cell support in patients with breast cancer.
Cancer treatment reviews 1998;24(4):249-63.
1998: Kuerer H M; Newman L A; Buzdar A U; Dhingra K; Hunt K K; Buchholz T A; Binkley S M; Strom E A; Ames F C; Ross M I; Feig B W; McNeese M D; Hortobagyi G N; Singletary S E
Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
The cancer journal from Scientific American 1998;4(4):230-6.
1998: Chang S; Parker S L; Pham T; Buzdar A U; Hursting S D
Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992.
Cancer 1998;82(12):2366-72.
1998: Diaz-Canton E A; Valero V; Rahman Z; Rodriguez-Monge E; Frye D; Smith T; Buzdar A U; Hortobagyi G N
Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):413-8.
1998: Buzdar A U
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
American journal of clinical oncology 1998;21(2):161-6.
1998: Buzdar A U; Hortobagyi G
Update on endocrine therapy for breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):527-34.
1998: Buzdar A U; Hortobagyi G N
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):348-53.
1998: Hortobagyi G N; Buzdar A U
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Cancer investigation 1998;16(6):385-90.
1997: Kinney A Y; Sahin A; Vernon S W; Frankowski R F; Annegers J F; Hortobagyi G N; Buzdar A U; Frye D K; Dhingra K
The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.
Cancer 1997;80(12):2240-9.
1997: Roseman B J; Buzdar A U; Singletary S E
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Journal of surgical oncology 1997;66(3):215-20.
1997: Hortobagyi G N; Willey J; Rahman Z; Holmes F A; Theriault R L; Buzdar A U
Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-65-S17-68.
1997: Buzdar A U; Hortobagyi G N; Asmar L; Theriault R L; Rahman Z; McNeese M; Singletary S; Ames F
Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
Seminars in oncology 1997;24(5 Suppl 17):S17-31-S17-34.
1997: Rahman Z U; Frye D K; Buzdar A U; Smith T L; Asmar L; Champlin R E; Hortobagyi G N
Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(10):3171-7.
1997: Herrada J; Iyer R B; Atkinson E N; Sneige N; Buzdar A U; Hortobagyi G N
Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(9):1565-9.
1997: Inoue T; Kim E E; Wallace S; Yang D J; Wong F C; Bassa P; Buzdar A U; Podoloff D A
Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer.
Clinical imaging 1997;21(5):332-6.
1997: Fleming R Y; Asmar L; Buzdar A U; McNeese M D; Ames F C; Ross M I; Singletary S E
Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma.
Annals of surgical oncology 1997;4(6):452-61.
1997: Hortobagyi G N; Holmes F A; Theriault R L; Rahman Z; Buzdar A U
Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer.
Seminars in oncology 1997;24(4 Suppl 11):S11-13-S11-19.
1997: Buzdar A U; Jonat W; Howell A; Plourde P V
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
The Journal of steroid biochemistry and molecular biology 1997;61(3-6):145-9.
1997: Hortobagyi G N; Holmes F A; Ibrahim N; Champlin R; Buzdar A U
The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer.
Seminars in oncology 1997;24(1 Suppl 3):S30-3.
1997: Buzdar A U; Jones S E; Vogel C L; Wolter J; Plourde P; Webster A
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Cancer 1997;79(4):730-9.
1997: Ueno N T; Buzdar A U; Singletary S E; Ames F C; McNeese M D; Holmes F A; Theriault R L; Strom E A; Wasaff B J; Asmar L; Frye D; Hortobagyi G N
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center.
Cancer chemotherapy and pharmacology 1997;40(4):321-9.
1996: Diamandidou E; Buzdar A U; Smith T L; Frye D; Witjaksono M; Hortobagyi G N
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2722-30.
1996: Holmes F A; Madden T; Newman R A; Valero V; Theriault R L; Fraschini G; Walters R S; Booser D J; Buzdar A U; Willey J; Hortobagyi G N
Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2713-21.
1996: Inoue T; Kim E E; Wallace S; Yang D J; Wong F C; Bassa P; Cherif A; Delpassand E; Buzdar A; Podoloff D A
Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study.
Cancer biotherapy & radiopharmaceuticals 1996;11(4):235-45.
1996: Buzdar A U; Plourde P V; Hortobagyi G N
Aromatase inhibitors in metastatic breast cancer.
Seminars in oncology 1996;23(4 Suppl 9):28-32.
1996: Greenberg P A; Hortobagyi G N; Smith T L; Ziegler L D; Frye D K; Buzdar A U
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(8):2197-205.
1996: Buzdar A; Jonat W; Howell A; Jones S E; Blomqvist C; Vogel C L; Eiermann W; Wolter J M; Azab M; Webster A; Plourde P V
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(7):2000-11.
1996: Bassa P; Kim E E; Inoue T; Wong F C; Korkmaz M; Yang D J; Wong W H; Hicks K W; Buzdar A U; Podoloff D A
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(6):931-8.
1996: Buzdar A U; Smith R; Vogel C; Bonomi P; Keller A M; Favis G; Mulagha M; Cooper J
Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
Cancer 1996;77(12):2503-13.
1996: Payne J Y; Holmes F; Cohen P R; Gagel R; Buzdar A; Dhingra K
Paclitaxel: severe mucocutaneous toxicity in a patient with hyperbilirubinemia.
Southern medical journal 1996;89(5):542-5.
1996: Ibrahim N K; Frye D K; Buzdar A U; Walters R S; Hortobagyi G N
Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Archives of internal medicine 1996;156(8):882-8.
1996: Mora E M; Singletary S E; Buzdar A U; Johnston D A
Aggressive therapy for locoregional recurrence after mastectomy in stage II and III breast cancer patients.
Annals of surgical oncology 1996;3(2):162-8.
1995: Valero V; Holmes F A; Walters R S; Theriault R L; Esparza L; Fraschini G; Fonseca G A; Bellet R E; Buzdar A U; Hortobagyi G N
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2886-94.
1995: Buzdar A U; Singletary S E; Booser D J; Frye D K; Wasaff B; Hortobagyi G N
Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.
Surgical oncology clinics of North America 1995;4(4):715-34.
1995: Ibrahim N K; Buzdar A U
Aromatase inhibitors: current status.
American journal of clinical oncology 1995;18(5):407-17.
1995: Dhingra K; Fritsche H; Murray J L; LoBuglio A F; Khazaeli M B; Kelley S; Tepper M A; Grasela D; Buzdar A; Valero V
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin.
Cancer research 1995;55(14):3060-7.
1995: Buzdar A U; Holmes F A; Hortobagyi G N
Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Seminars in oncology 1995;22(3 Suppl 6):101-4.
1995: Jaiyesimi I A; Buzdar A U; Decker D A; Hortobagyi G N
Use of tamoxifen for breast cancer: twenty-eight years later.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):513-29.
1994: Buzdar A U; Esparza L; Natale R; Cody R; Calzone K; Benson A B; Sheehan T; Berry W
Lorazepam-enhancement of the antiemetic efficacy of dexamethasone and promethazine. A placebo-controlled study.
American journal of clinical oncology 1994;17(5):417-21.
1994: Hortobagyi G N; Holmes F A; Theriault R L; Buzdar A U
Use of Taxol (paclitaxel) in breast cancer.
Oncology 1994;51 Suppl 1():29-32.
1994: Buzdar A U; Hortobagyi G N; Frye D; Ho D; Booser D J; Valero V; Holmes F A; Birmingham B K; Bui K; Yeh C
Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):50-4.
1994: Bastarrachea J; Hortobagyi G N; Smith T L; Kau S W; Buzdar A U
Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer.
Annals of internal medicine 1994;120(1):18-25.
1994: Buzdar A U; Kau S; Hortobagyi G N; Theriault R L; Booser D; Holmes F A; Walters R; Krakoff I H
Phase I trial of droloxifene in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 1994;33(4):313-6.
1994: Yang D J; Li C; Kuang L R; Price J E; Buzdar A U; Tansey W; Cherif A; Gretzer M; Kim E E; Wallace S
Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues.
Life sciences 1994;55(1):53-67.
1994: Dhingra K; Fritsche H; Murray J L; LoBuglio A F; Khazaeli M B; Kelley S; Tepper M; Greene D; Booser D; Buzdar A
Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study.
Advances in experimental medicine and biology 1994;353():193-202.
1994: Dhingra K; Valero V; Gutierrez L; Theriault R; Booser D; Holmes F; Buzdar A; Fraschini G; Hortobagyi G
Phase II study of deoxyspergualin in metastatic breast cancer.
Investigational new drugs 1994;12(3):235-41.
1993: Buzdar A U; Kau S W; Smith T L; Ames F; Singletary E; Strom E; McNeese M; Hortobagyi G N
The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer.
Cancer 1993;71(11):3680-4.
1992: Theriault R L; Stallings C B; Buzdar A U
Pregnancy and breast cancer: clinical and legal issues.
American journal of clinical oncology 1992;15(6):535-9.
1992: Jaiyesimi I A; Buzdar A U; Sahin A A; Ross M A
Carcinoma of the male breast.
Annals of internal medicine 1992;117(9):771-7.
1992: Buzdar A U; Hortobagyi G N; Kau S W; Smith T L; Fraschini G; Holmes F A; Gutterman J U; Hug V M; Singletary S E; Ames F C
Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1540-6.
1992: Jaiyesimi I A; Buzdar A U; Hortobagyi G
Inflammatory breast cancer: a review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):1014-24.
1992: Jaiyesimi I A; Buzdar A U
Adjuvant chemotherapy in high-risk breast cancer patients with ten or more positive lymph nodes.
American journal of clinical oncology 1992;15(2):180-3.
1992: Walters R S; Frye D; Buzdar A U; Holmes F A; Hortobagyi G N
A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma.
Cancer 1992;69(2):476-81.
1992: Buzdar A U; Kau S W; Hortobagyi G N; Ames F C; Holmes F A; Fraschini G; Hug V; Theriault R L; McNeese M D; Singletary S E
Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.
Cancer 1992;69(2):448-52.
1992: Simmons J R; Buzdar A U; Ota D M; Marts K; Hortobagyi G N
Complications associated with indwelling catheters.
Medical and pediatric oncology 1992;20(1):22-5.
1991: Holmes F A; Walters R S; Theriault R L; Forman A D; Newton L K; Raber M N; Buzdar A U; Frye D K; Hortobagyi G N
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
Journal of the National Cancer Institute 1991;83(24):1797-805.
1991: Fraschini G; Holmes F A; Esparza L; Theriault R L; Buzdar A U; Hortobagyi G N
Phase I-II study of high-dose etoposide in patients with refractory breast cancer.
Investigational new drugs 1991;9(4):365-7.
1991: Macheledt J E; Buzdar A U; Hortobagyi G N; Frye D K; Gutterman J U; Holmes F A
Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.
Breast cancer research and treatment 1991;18(3):165-70.
1991: Lamki L M; Buzdar A U; Singletary S E; Rosenblum M G; Bhadkamkar V; Esparza L; Podoloff D A; Zukiwski A; Hortobagyi G N; Murray J L
Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1991;32(7):1326-32.
1991: Ziegler L D; Buzdar A U
Recent advances in the treatment of breast cancer.
The American journal of the medical sciences 1991;301(5):337-52.
1991: Ziegler L D; Buzdar A U
Current status of adjuvant therapy of early breast cancer.
American journal of clinical oncology 1991;14(2):101-10.
1990: Wallerstein R; Spitzer G; Dunphy F; Huan S; Hortobagyi G; Yau J; Buzdar A; Holmes F; Theriault R; Ewer M
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(11):1782-8.
1990: Dunphy F R; Spitzer G; Buzdar A U; Hortobagyi G N; Horwitz L J; Yau J C; Spinolo J A; Jagannath S; Holmes F; Wallerstein R O
Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1207-16.
1990: Holmes F A; Fritsche H A; Loewy J W; Geitner A M; Sutton R C; Buzdar A U; Hortobagyi G N
Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(6):1025-35.
1990: Sutton R; Buzdar A U; Hortobagyi G N
Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients.
Cancer 1990;65(4):847-50.
1990: Buzdar A U; McNeese M D; Hortobagyi G N; Smith T L; Kau S; Fraschini G; Hug V; Ellerbroek N; Holmes F A; Ames F
Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?
Cancer 1990;65(3):394-9.
1990: Buzdar A U; Hortobagyi G N; Esparza L T; Holmes F A; Ro J S; Fraschini G; Lichtiger B
Elliptinium acetate in metastatic breast cancer--a phase II study.
Oncology 1990;47(2):101-4.
1990: Hortobagyi G N; Theriault R L; Frye D; Walters R S; Fraschini G; Tashima C K; Ro J S; Salewski E; Buzdar A U
Pirarubicin in combination chemotherapy for metastatic breast cancer.
American journal of clinical oncology 1990;13 Suppl 1():S54-6.
1990: Koh E H; Buzdar A U; Ames F C; Singletary S E; McNeese M D; Frye D; Holmes F A; Fraschini G; Hug V; Theriault R L
Inflammatory carcinoma of the breast: results of a combined-modality approach--M.D. Anderson Cancer Center experience.
Cancer chemotherapy and pharmacology 1990;27(2):94-100.
1990: Buzdar A U
Current status of endocrine treatment of carcinoma of the breast.
Seminars in surgical oncology 1990;6(2):77-82.
1990: Vanek N; Hortobagyi G N; Buzdar A U
Radiotherapy enhances the toxicity of aminoglutethimide.
Medical and pediatric oncology 1990;18(2):162-4.
1990: Theriault R L; Buzdar A U
Acute superior vena caval thrombosis after central venous catheter removal: successful treatment with thrombolytic therapy.
Medical and pediatric oncology 1990;18(1):77-80.
1989: Ang P T; Buzdar A U; Smith T L; Kau S; Hortobagyi G N
Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(11):1677-84.
1989: Patel H Z; Buzdar A U; Hortobagyi G N
Role of adjuvant chemotherapy in male breast cancer.
Cancer 1989;64(8):1583-5.
1989: Hortobagyi G N; Hug V; Buzdar A U; Kau S W; Holmes F A; Fritsche H A
Sequential cyclic combined hormonal therapy for metastatic breast cancer.
Cancer 1989;64(5):1002-6.
1989: Buzdar A U; Kau S W; Smith T L; Hortobagyi G N
Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.
American journal of clinical oncology 1989;12(2):123-8.
1989: Theriault R L; Hortobagyi G N; Fritsche H A; Frye D; Martinez R; Buzdar A U
The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy.
Cancer 1989;63(5):828-35.
1989: Chu P S; Buzdar A U; Hortobagyi G N
Trilostane with hydrocortisone in treatment of metastatic breast cancer.
Breast cancer research and treatment 1989;13(2):117-21.
1989: Hortobagyi G N; Frye D; Buzdar A U; Ewer M S; Fraschini G; Hug V; Ames F; Montague E; Carrasco C H; Mackay B
Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Cancer 1989;63(1):37-45.
1988: Hortobagyi G N; Ames F C; Buzdar A U; Kau S W; McNeese M D; Paulus D; Hug V; Holmes F A; Romsdahl M M; Fraschini G
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy.
Cancer 1988;62(12):2507-16.
1988: Theriault R L; Hortobagyi G N; Kau S W; Holmes F A; Hug V; Fraschini G; Jabboury K; Buzdar A U
Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer.
Cancer 1988;62(10):2105-10.
1988: Buzdar A U; Hortobagyi G N; Smith T L; Kau S; Marcus C; Holmes F A; Hug V; Fraschini G; Ames F C; Martin R G
Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
Cancer 1988;62(10):2098-104.
1988: Hortobagyi G N; Buzdar A U
Management of locally advanced breast cancer.
American journal of clinical oncology 1988;11(5):597-601.
1988: Fraschini G; Holmes F A; Buzdar A U; Hug V; Hortobagyi G N
Cisplatin in combination with continuous infusion vinblastine for refractory breast cancer.
American journal of clinical oncology 1988;11(4):448-50.
1988: Buzdar A U
Chemotherapeutic approaches to advanced breast cancer.
Seminars in oncology 1988;15(3 Suppl 4):65-70.
1988: Berté E; Buzdar A U; Smith T L; Hortobagyi G N
Bilateral primary breast cancer in patients treated with adjuvant therapy.
American journal of clinical oncology 1988;11(2):114-8.
1988: Fraschini G; Charnsangavej C; Carrasco C H; Buzdar A U; Jabboury K W; Hortobagyi G N
Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver.
American journal of clinical oncology 1988;11(1):34-8.
1988: Buzdar A U; Marcus C; Holmes F; Hug V; Hortobagyi G
Phase II evaluation of Ly156758 in metastatic breast cancer.
Oncology 1988;45(5):344-5.
1987: Hortobagyi G N; Buzdar A U; Frye D; Hug V; Fraschini G; Ames F C; Montague E; Gutterman J U; Martin R G
Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial.
Cancer 1987;60(11):2596-604.
1987: Holmes F A; Yap H Y; Esparza L; Buzdar A U; Blumenschein G R; Hug V; Hortobagyi G N
Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy.
Cancer 1987;59(12):1992-9.
1986: Holmes F A; Esparza L; Yap H Y; Buzdar A U; Blumenschein G R; Hortobagyi G N
A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer.
Cancer chemotherapy and pharmacology 1986;18(2):157-61.
1984: Holmes F A; Yap H Y; Esparza L; Buzdar A U; Hortobagyi G N; Blumenschein G R
Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Seminars in oncology 1984;11(3 Suppl 1):28-31.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Aman Buzdar

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Aman Buzdar (preview)

All Publications